Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Pallawi Torka, MD, Priyank P. Patel, MD, Wei Tan, Gregory Wilding, Seema A. Bhat, MD, Myron S. Czuczman, MD, Kelvin P. Lee, MD, George Deeb, MD, Vishala T. Neppalli, MD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 3975.

https://doi.org/10.1182/blood.V126.23.3975.3975

Published: 2015

Journal Articles

Intense Cytarabine-Based Chemo-Immunotherapy, Central Nervous System (CNS) Prophylaxis and Early High-Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS) in First Remission Are Associated with an Improved Clinical Outcome in Double-Hit (DHL)/Triple-Hit (THL) Diffuse Large B-Cell Lymphoma (DLBCL)

Priyank P. Patel, MD, Pallawi Torka, MD, Vishala T. Neppalli, MD, George Deeb, MD, Sheila N.J. Sait, PhD, AnneMarie W. Block, PhD, Seema A. Bhat, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2014) 124 (21): 3031.

https://doi.org/10.1182/blood.V124.21.3031.3031

Published: 2014

Journal Articles

Bone Marrow Core Biopsy Adequacy and Variability in the United Stated and Canada: A Multicenter Retrospective Study

Mihai Merzianu, MD, Richard Cheney, MD, Adrienne Groman, MS, George Deeb, MD, Gregory Wilding, PhD, Claudiu Cotta, MD, Ramila Amre, MD, Manjula Balasubramanian, MD, Guilherme Brandao, MD, Russell K. Brynes, MD, Sindhu Cherian, MD, Elizabeth Courville, MD, David Czuchlewski, MD, Guang Fan, MD PhD, David Grier, MD, Daniela Hoehn, MD PhD, Robert E Hutchison, MD, Kedar V. Inamdar, MD PhD, Ridas Juskevicius, MD, Prabhjot Kaur, MD, John Lazarchick, MD, Michael R Lewis, MD, Rodney R. Miles, MD PhD, Jerome B. Myers, MD PhD, Michel Nasr, MD, Hina Naushad, MD, Horatiu Olteanu, MD PhD, Attilio Orazi, MD, Vishnu VB Reddy, MD, Valentin G Robu, MD, Gratian Salaru, MD, Julie Teruya-Feldstein, MD, Neerja Vajpayee, MD, Jeffrey Vos, MD, Ling Zhang, MD, Shanxing Zhang, MD PhD, Ashley V Sedelmeyer, MHA, Vivian Arguello, MD, Le Aye, DO, Sharon Barouk, MA, Elisa F Brega, MD PhD, Richie Carpenter, BS, James E. Coad, MD, Alana DiPonio, MT, Fernandez Garcia, MS, MD, John Grantham, BS, Sinisa Ivelja, MD, Robert McKenna, MD, Kieran Sultan, MD, Matthew B Thomsen, MPH, Jie Xu, MD PhD, LoAnn Peterson, MD, Vishala T. Neppalli, MD

Blood (2014) 124 (21): 1316.

https://doi.org/10.1182/blood.V124.21.1316.1316

Published: 2014

Journal Articles

Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)

Shipra Gandhi, MD, Vishala T. Neppalli, MD, George Deeb, MD, Myron S. Czuczman, MD, Francisco J Hernandez-Ilizaliturri, MD

Blood (2013) 122 (21): 5064.

https://doi.org/10.1182/blood.V122.21.5064.5064

Published: 2013

Journal Articles

Apoptotic and Non-Apoptotic Cellular Pathways Executed by Bortezomib (BTZ) in Rituximab-Resistant Lymphomas

Juan Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Cory Mavis, BSc, MSc, Natalie M Czuczman, Karen E Thudium, George Deeb, MD, John Gibbs, MD, Myron S. Czuczman, MD

Blood (2011) 118 (21): 4967.

https://doi.org/10.1182/blood.V118.21.4967.4967

Published: 2011

Journal Articles

Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples

Matthew J. Barth, MD, Gopichand Pendurty, MD, Cory Mavis, BSc, MSc, Natalie M Czuczman, John Gibbs, MD, George Deeb, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2011) 118 (21): 4972.

https://doi.org/10.1182/blood.V118.21.4972.4972

Published: 2011

Journal Articles

Blastoid Variant of Mantle Cell Lymphoma (MCL) Is Associated with P53 Abnormalities and Have a Shorter Progression-Free Survival (PFS) and Overall Survival (OS) Despite Upfront Chemo-Immunotherapy Followed by High Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS)

Lyudmyla Derby, MD, Gopichand Pendurti, MD, George Deeb, MD, Sheila Sait, PhD, Annmarie Block, PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2010) 116 (21): 1773.

https://doi.org/10.1182/blood.V116.21.1773.1773

Published: 2010

Journal Articles

The Expression of Bcl-6 In Diffuse Large B Cell Lymphoma (DLBCL) Is Associated with Improved Progression Free Survival and Overall Survival Following Front-Line Rituximab-Chemotherapy

Pooja Advani, MBBS, Nuttapong Ngamphaiboon, MD, Sulada Pukiat, MD, Julio Chavez, MD, George Deeb, MD, Anjana Elefante, Pharm, D, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2010) 116 (21): 5073.

https://doi.org/10.1182/blood.V116.21.5073.5073

Published: 2010

Journal Articles

Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenografts, and Primary Tumor Cells Derived From Patients with B-Cell Non-Hodgkin Lymphoma (NHL)

Matthew Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD, Cory Mavis, BSc, MSc, Ping-Chiao Tsai, John Gibbs, MD, George Deeb, MD, Myron S. Czuczman, MD

Blood (2010) 116 (21): 3917.

https://doi.org/10.1182/blood.V116.21.3917.3917

Published: 2010

Journal Articles

MLN2238, a Novel and Potent Proteasome Inhibitor, Induces Caspase-Dependent Cell Death, Cell-Cycle Arrest, and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Chemotherapy Sensitive or Resistant B-Cell Lymphoma Cell Lines

Juan Gu, PhD, Patil Ritesh, MD, MPH, Cory Mavis, BSc, MSc, George Deeb, MD, John Gibbs, MD, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD

Blood (2010) 116 (21): 3939.

https://doi.org/10.1182/blood.V116.21.3939.3939

Published: 2010

Journal Articles

BCL-2 Expression at the Time of Diagnosis Affects the Clinical Outcome of Patients with Germinal Center and Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Chemo-Immunotherpy

Sulada Pukiat, MD, Nuttapong Ngamphaiboon, MD, Pooja Advani, MBBS, Julio Chavez, MD, George Deeb, MD, Anjana Elefante, Pharm, D, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2010) 116 (21): 3130.

https://doi.org/10.1182/blood.V116.21.3130.3130

Published: 2010

Journal Articles

Diverse Roles of Hepatocyte Growth Factor (HGF) in Normal Karyotype Acute Myeloid Leukemia (AML).

Ian McInnis, Theresa Hahn, PhD, Anasitasia Ioane, Ashleigh Lamson, Deepika Lal, Laurie Ann Ford, Sheila NJ Sait, Petr Starostik, MD, George Deeb, MD, Meir Wetzler, MD, Terry Mashtare, Jr., Eunice S. Wang, M.D.

Blood (2009) 114 (22): 3107.

https://doi.org/10.1182/blood.V114.22.3107.3107

Published: 2009

Journal Articles

CD19 Expression in t(8;21)-Negative Acute Myeloid Leukemia Is Not Restricted to Cytogenetically Aberrant Populations.

Jawad Francis, MD, Avinash Dharmadhikari, Sheila N.J. Sait, PhD, George Deeb, MD, Paul K. Wallace, MS, PhD, James E. Thompson, MD, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2009) 114 (22): 4128.

https://doi.org/10.1182/blood.V114.22.4128.4128

Published: 2009

Journal Articles

CD33-Negative Acute Myeloid Leukemia (AML) Has Similar Characteristics to CD33-Positive Disease.

Cecilia Y. Arana Yi, MD, Wei Tan, Ph.D., Gregory Wilding, Ph.D., Laurie Ann Ford, Sheila N.J. Sait, PhD, AnneMarie W. Block, PhD, George Deeb, MD, Paul K. Wallace, MS, PhD, Petr Starostik, MD, James E. Thompson, MD, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2009) 114 (22): 4129.

https://doi.org/10.1182/blood.V114.22.4129.4129

Published: 2009

Journal Articles

Expression of Vascular Endothelial Growth Factor Receptors VEGFR-1 and VEGFR-2 Are Prognostic Factors in Normal Karyotype Acute Myeloid Leukemia (NK-AML)

Kellie M. Demock, Joseph Marinaro, Amanda Sobczyk, Laurie Ann Ford, Meir Wetzler, MD, George Deeb, MD, Lili Tian, Eunice S. Wang, MD

Blood (2008) 112 (11): 2552.

https://doi.org/10.1182/blood.V112.11.2552.2552

Published: 2008

Journal Articles

Hypoxia-Inducible Factor-1 Alpha (HIF-1α) and HIF-2α Are Independent Prognostic Factors for Normal Karyotype Acute Myeloid Leukemia (NK AML)

Kellie M. Demock, Joseph Marinaro, Ian McInnis, Laurie Ann Ford, Meir Wetzler, MD, Lili Tian, George Deeb, MD, Eunice S. Wang, MD

Blood (2008) 112 (11): 2553.

https://doi.org/10.1182/blood.V112.11.2553.2553

Published: 2008

Journal Articles

Frequent Molecular Aberrations in Normal Karyotype (NC) Precursor B-Cell Acute Lymphoblastic Leukemia (pB-ALL) Detected by Comparative Genomic Hybridization.

Amer Zeidan, MD, Dan Gaile, PhD, Jeffrey M. Conroy, MS, Devin E. McQuaid, MS, Eunice S. Wang, MD, George Deeb, MD, Paul K. Wallace, PhD, Sheila N.J. Sait, PhD, Norma J. Nowak, PhD, Meir Wetzler, MD

Blood (2007) 110 (11): 4270.

https://doi.org/10.1182/blood.V110.11.4270.4270

Published: 2007

NARROW

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Bone Marrow Core Biopsy Adequacy and Variability in the United Stated and Canada: A Multicenter Retrospective Study

Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)

Apoptotic and Non-Apoptotic Cellular Pathways Executed by Bortezomib (BTZ) in Rituximab-Resistant Lymphomas

Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples

Blastoid Variant of Mantle Cell Lymphoma (MCL) Is Associated with P53 Abnormalities and Have a Shorter Progression-Free Survival (PFS) and Overall Survival (OS) Despite Upfront Chemo-Immunotherapy Followed by High Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS)

The Expression of Bcl-6 In Diffuse Large B Cell Lymphoma (DLBCL) Is Associated with Improved Progression Free Survival and Overall Survival Following Front-Line Rituximab-Chemotherapy

MLN2238, a Novel and Potent Proteasome Inhibitor, Induces Caspase-Dependent Cell Death, Cell-Cycle Arrest, and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Chemotherapy Sensitive or Resistant B-Cell Lymphoma Cell Lines

BCL-2 Expression at the Time of Diagnosis Affects the Clinical Outcome of Patients with Germinal Center and Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Chemo-Immunotherpy

Diverse Roles of Hepatocyte Growth Factor (HGF) in Normal Karyotype Acute Myeloid Leukemia (AML).

CD19 Expression in t(8;21)-Negative Acute Myeloid Leukemia Is Not Restricted to Cytogenetically Aberrant Populations.

CD33-Negative Acute Myeloid Leukemia (AML) Has Similar Characteristics to CD33-Positive Disease.

Expression of Vascular Endothelial Growth Factor Receptors VEGFR-1 and VEGFR-2 Are Prognostic Factors in Normal Karyotype Acute Myeloid Leukemia (NK-AML)

Hypoxia-Inducible Factor-1 Alpha (HIF-1α) and HIF-2α Are Independent Prognostic Factors for Normal Karyotype Acute Myeloid Leukemia (NK AML)

Frequent Molecular Aberrations in Normal Karyotype (NC) Precursor B-Cell Acute Lymphoblastic Leukemia (pB-ALL) Detected by Comparative Genomic Hybridization.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only